FiercePharma

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...
Healthline

Side Effects of Bydureon BCise (Exenatide Extended-Release): What You Need to Know

If you have type 2 diabetes, your doctor may suggest Bydureon BCise (exenatide extended-release) as a treatment option. Along with other factors, you may have questions about possible side effects of ...
MM&M

Bydureon catching on among endos but low profits expected, Amylin says

Amylin said weekly diabetes shot Bydureon, launched in February, is gaining market share among influential physicians but expects the med’s profit margins to be low for some time. Bydureon brought in ...
Monthly Prescribing Reference

Bydureon Single Dose Trays to Be Discontinued

The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays. The 2mg Single Dose Tray ...
Reuters

AstraZeneca says FDA approves Bydureon pen for type 2 diabetes

Indonesia will increase imports of U.S. food and commodities and reduce orders from countries the Southeast Asian nation currently buys the products from, chief economic minister Airlangga Hartarto ...
FiercePharma

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...